Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first-or second-line treatment

British Journal of Cancer

Volumn 105, Issue 10, 2011, Pages 1495-1502

  Bennett, L ^a   Zhao, Z ^b   Barber, B ^b   Zhou, X ^a   Peeters, M ^c   Zhang, J ^a   Xu, F ^b   Wiezorek, J ^b   Douillard, J Y ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b AMGEN INC   (United States)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

colorectal cancer; panitumumab; quality of life

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN TOXICITY; VISUAL ANALOG SCALE; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE;

EID: 80755146080     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.409     Document Type: Article

References (25)

1. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC (2006) Dermatologic side effects associated with the epidermal growth factor receptors inhibitors. J Am Acad Dermatol 55: 657-670 (Pubitemid 44436627)
2. Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634
3. Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, Mazzocchi M, Zaniboni A (2010) Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes 8: 40
4. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuh G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671
5. Byrne C, Griffin A, Blazeby J, Conroy T, Efficace F (2007) Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer. Eur J Surg Oncol 33: S95-S104 (Pubitemid 350216637)
6. Cella DF (1995) Measuring quality of life in palliative care. Semin Oncol 22: 73-81
7. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35: 1095-1108 (Pubitemid 127453463)
8. Douillard JY, Siena S, Caissdy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasin̈ska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) verus FOLFOX4 alone as a first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705
9. Folprecht G, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Zubel A, Van Cutsem E (2009) Cetuximab plus FOLFIRI first-line in patients (pts) with metastatic colorectal cancer (mCRC): a quality of life (QoL) analysis of the CRYSTAL trial. J Clin Oncol 127: 15s Abstract 4076
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffling S, Holmgren E, Ferrara N, Fyfe F, Rodgers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 (Pubitemid 38702844)
11. Kabbinavar FF, Wallace JF, Holmgren E, Yi J, Cella D, Yost KJ, Hurwitz HI (2008) Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluoro-uracil and leucovorin for metastatic colorectal cancer. Oncologist 13: 1021-1029
12. Karapetis CS, Khambat-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefits from cetuximab in advanced colorectal cancer. N Eng J Med 359: 1757-1765
13. Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ (2004) Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 13: 1247-1253 (Pubitemid 39149608)
14. National Cancer Institute, National Institutes of Health, Department of Health and Human Services (2006) Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, version 3.0.
15. Bethesda, MD Odom D, Barber B, Bennett L, Peeters M, Zhao Z, Kaye J, Wolf M, Wiezorek J (2011) Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis 26: 173-181
16. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase III study of panitumumab with FOLFIRI vs FOLFIRI alone as a second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713
17. Petrou S, Hockley C (2005) An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 14: 1169-1189 (Pubitemid 41645379)
18. Pickard AS, Neary MP, Cella D (2007a) Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 5: 70
19. Pickard AS, Wilke CT, Lin HW, Lloyd A (2007b) Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 25: 365-384 (Pubitemid 46744468)
20. Saltz LB, Clarke S, D́az-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019
21. Siddiqui O, Hung H, O'Neill R (2009) MMRM vs LOCF: a comphrensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 19: 227-246
22. Siena S, Peeters M, van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97: 1469-1474 (Pubitemid 350175845)
23. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomised Phase III MAX Study. J Clin Oncol 28: 3191-3198
24. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Teipar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatatic colorectal cancer. N Engl J Med 360: 1408-1417
25. Van Cutsem E, Nordlinger B, Cervantes A, ESMO Guidelines Working Group (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21: v93-v97